What Is NAD+?

NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme present in every living cell that serves two distinct roles: a redox carrier shuttling electrons through glycolysis and the citric acid cycle to drive ATP synthesis, and a consumed substrate for sirtuins and PARPs — enzymes governing DNA repair, gene expression, and metabolic adaptation. Intracellular NAD+ concentrations decline by approximately 50% between early adulthood and midlife across liver, muscle, and brain tissue, a decline mechanistically linked to age-related functional loss.[3][4] Injectable NAD+ (intravenous or subcutaneous) bypasses the poor oral bioavailability of the molecule itself to achieve rapid systemic repletion.

Note on nomenclature: NAD+ is the oxidized form. NADH is the reduced form. Precursors such as NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) raise the intracellular NAD+ pool by different biosynthetic routes. The WMP product is NAD+ itself — not a precursor.

The Short Answer

NAD+ is a central metabolic coenzyme that declines with age; restoring it activates sirtuins (SIRT1–7) and PARPs that drive DNA repair, mitochondrial biogenesis, and metabolic homeostasis. Animal studies consistently show NAD+ repletion extends lifespan and healthspan.[1] The first large randomized human trial of an NAD+ precursor (NMN, Science 2021) reported improved skeletal muscle insulin signaling in prediabetic women.[2] Human evidence for injectable NAD+ specifically remains limited to pilot and observational reports; no placebo-controlled RCT has been published.

Key Concepts

Molecular function — two separate roles:

NAD+ acts as a redox carrier that accepts electrons from NADH-generating reactions (glycolysis, β-oxidation, the TCA cycle) and transfers them to Complex I of the mitochondrial electron transport chain, driving ATP synthesis. This cycling does not consume NAD+ — NADH is re-oxidized back to NAD+.

NAD+ is consumed (not cycled) by three enzyme classes:[1]

• Sirtuins (SIRT1–7): NAD+-dependent deacylases. SIRT1 deacetylates PGC-1α to drive mitochondrial biogenesis; SIRT3 activates antioxidant enzymes in mitochondria. Both require NAD+ as a co-substrate and are silenced when NAD+ falls.
• PARPs (poly(ADP-ribose) polymerases): Consume large quantities of NAD+ during DNA strand-break repair. Accumulated DNA damage in aging chronically activates PARPs, accelerating NAD+ depletion.
• CD38/CD157: Ectoenzymes that hydrolyze NAD+; their expression increases with age and inflammatory signaling ("inflammaging"), further depleting the available pool.

Age-related decline:
NAD+ drops ~50% in rodent liver, kidney, and brain between young and aged animals, with oxidative stress markers rising inversely.[3] Human blood NAD+ follows a similar downward trajectory.[4] The combined drain of PARP activation and rising CD38 outpaces the salvage pathway's replenishment capacity.

Why injectable over oral?
Oral NAD+ is substantially degraded by gut-wall enzymes and has low systemic bioavailability. Oral precursors (NMN, NR) are better absorbed and converted intracellularly. Injectable NAD+ bypasses gut metabolism entirely, producing rapid blood-level elevation. This makes it useful when speed of repletion is the research objective, or when gut function is compromised.

Human Evidence

No placebo-controlled RCT of injectable NAD+ has been published. Observational reports describe IV NAD+ infusion in substance withdrawal and neurodegenerative contexts; these lack the design to establish efficacy.

Dosage Reference

Educational reference only. Injectable NAD+ dosing is not established by clinical trials. The following reflects common research approaches extrapolated from preclinical data and observational practice.

Reconstitution (1000 mg vial): Add 10.0 mL bacteriostatic water → 100 mg/mL. On a U-100 insulin syringe, 1 unit = 0.01 mL = 1 mg.

Subcutaneous: Rotate sites; 250–500 mg once daily is common in community research protocols. Large volumes (>2 mL per site) should be split across multiple injection sites.

Intravenous: 500–1000 mg diluted in 250–500 mL normal saline; infuse over 1–4 hours under clinical supervision. Slowing the drip rate resolves the flush/nausea/chest-tightness that are rate-dependent infusion reactions.

For full reconstitution tables and syringe math, see the NAD+ 1000 mg Dosage Protocol.

Safety Profile

IV infusion reactions (rate-dependent): Flushing, chest tightness, nausea, and palpitations — common but transient; managed by slowing the infusion rate. No serious adverse events attributable to NAD+ are described in the available literature at research doses.

Subcutaneous: Site burning and local irritation are frequently reported; NAD+ solution is acidic (pH ~3–4), which contributes to injection-site discomfort.

Contraindications and cautions:

• No formal human pharmacokinetic or toxicology studies for injectable NAD+
• Sirtuin activation and PARP modulation have potential relevance in oncology contexts — discuss with an oncologist before use if cancer history exists
• Pregnancy and lactation: no data; avoid
• Regulatory status: not FDA-approved as a drug in injectable form; classified as a research compound in the United States

Comparison: Injectable NAD+ vs. Oral Precursors

Frequently Asked Questions

What does NAD+ do in the cell?

NAD+ has two distinct functions. As a redox carrier it accepts electrons during glycolysis and the TCA cycle (becoming NADH), then donates them to Complex I of the mitochondrial electron transport chain to generate ATP. As a consumed substrate, it is cleaved by sirtuins and PARPs during DNA repair and gene regulation — processes that require adequate NAD+ to remain active. The interplay between these two functions determines how much NAD+ is available for each pathway.

Why does NAD+ decline with age?

Two converging factors accelerate consumption beyond what the salvage pathway replenishes: (1) accumulated DNA damage chronically activates PARP enzymes, which are high-throughput NAD+ consumers; (2) the ectoenzyme CD38, upregulated by the chronic low-grade inflammation of aging, hydrolyzes NAD+ in the extracellular space. The result is a net depletion that impairs sirtuin function and mitochondrial quality control.

Is injectable NAD+ better than taking NMN or NR?

For speed of plasma elevation, injectable NAD+ has a practical advantage. For human clinical evidence, oral NMN and NR are better studied (published RCTs exist). The choice depends on the research question: oral precursors are adequate for studying metabolic outcomes over weeks; injectable NAD+ is used when rapid repletion is the objective or when gut absorption cannot be assumed.

What side effects should researchers anticipate?

IV infusion: rate-dependent flushing, chest tightness, nausea, and palpitations — manageable by slowing the drip. Subcutaneous: burning and local irritation at injection sites due to the acidic pH of the solution. No formal safety trials exist for injectable NAD+.

Is NAD+ the same as a peptide?

No. NAD+ is a dinucleotide coenzyme (adenosine + nicotinamide connected by a phosphate bridge), not a peptide. It is included in the WMP catalog as a research compound alongside peptides because of its research and clinical overlap with the longevity and metabolic health space.